The iconic rise of Viagra has long been a benchmark of pharmaceutical success, but its position within the broader market now triggers questions about long-term returns . Alternative versions are eroding exclusivity , prompting anxieties that supporting companies heavily reliant to Viagra's previous influence could be a problematic move , especiall